Tom 13, Nr 1 (2018)
Sprawozdanie z konferencji / Sprawozdanie
Opublikowany online: 2018-03-23
Kardiologia prewencyjna w świetle najnowszych doniesień z Kongresu Europejskiego Towarzystwa Kardiologicznego w Barcelonie, 26–30 sierpnia 2017 roku
DOI: 10.5603/FC.2018.0018
Folia Cardiologica 2018;13(1):101-103.
Streszczenie
< p > < /p >
Słowa kluczowe: kardiologia prewencyjnaESC
Referencje
- Eikelboom JW, Connolly SJ, Bosch J, et al. COMPASS investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017; 377(14): 1319–1330.
- Ridker PM. How Common Is Residual Inflammatory Risk? Circ Res. 2017; 120(4): 617–619.
- Ridker PM, Everett BM, Thuren T, et al. CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017; 377(12): 1119–1131.
- Bowman L, Hopewell JC, Chen F, et al. HPS3/TIMI55–REVEAL Collaborative Group. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med. 2017; 377(13): 1217–1227.
- Dehghan M, Mente A, Zhang X, et al. Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. Lancet. 2017; 390(10107): 2050–2062.